Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study

Jackson, Lisa A.; Yu, Onchee; Belongia, Edward A.; Hambidge, Simon J.; Nelson, Jennifer C.; Baxter, Roger; Naleway, Allison L.; Nordin, James D.; Baggs, James; Iskander, John K.

doi:10.1186/1471-2334-9-165

Cited by 23 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 A VSD retrospective cohort study of 436 828 Td vaccinations demonstrated that medically attended local reactions, including cellulitis, were more common among persons who received a Td-containing vaccine within the last 5 years compared with a longer interval. 13 Another study assessed safety in 4524 Tdap-vaccinated health care workers during a pertussis outbreak in New England. 14 Overall, there was no difference in the rates of solicited moderate or severe injection site reactions, but there was an increase in redness, swelling, and subjective fever among patients who had received their prior Td-containing vaccine less than 2 years earlier.…”

Section: Discussionmentioning

confidence: 99%

Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations

Sukumaran

McCarthy

Kharbanda

et al. 2015

JAMA

View full text Add to dashboard Cite

Among women who received Tdap vaccination during pregnancy, there was no increased risk of acute adverse events or adverse birth outcomes for those who had been previously vaccinated less than 2 years before or 2 to 5 years before compared with those who had been vaccinated more than 5 years before. These findings suggest that relatively recent receipt of a prior tetanus-containing vaccination does not increase risk after Tdap vaccination in pregnancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations

Sukumaran

McCarthy

Kharbanda

et al. 2015

JAMA

View full text Add to dashboard Cite

show abstract

“…The frequency of reported adverse events from diphtheria toxoid–containing vaccines varies by vaccine formulation, dose of diphtheria toxoid, prior vaccination history, and prevaccination antidiphtheria toxoid antibody levels. Although local injection-site reactions are common, only a small proportion of these are clinically significant ( 226 ). Administration of diphtheria toxoid has not been associated with anaphylaxis.…”

Section: Vaccines For Prevention Of Pertussis Tetanus and Diphtherimentioning

confidence: 99%

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

et al. 2018

View full text Add to dashboard Cite

SummaryThis report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of tetanus, diphtheria, and pertussis in the United States. As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations and replaces all previously published reports and policy notes; it is intended for use by clinicians and public health providers as a resource. ACIP recommends routine vaccination for tetanus, diphtheria, and pertussis. Infants and young children are recommended to receive a 5-dose series of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines, with one adolescent booster dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Adults who have never received Tdap also are recommended to receive a booster dose of Tdap. Women are recommended to receive a dose of Tdap during each pregnancy, which should be administered from 27 through 36 weeks’ gestation, regardless of previous receipt of Tdap. After receipt of Tdap, adolescents and adults are recommended to receive a booster tetanus and diphtheria toxoids (Td) vaccine every 10 years to assure ongoing protection against tetanus and diphtheria.

show abstract

“…Injection site reactions, allergic reactions (evaluated separately in the outpatient, ED, and inpatient settings), syncope, and nonspecific reactions (eg, adverse effect of viral vaccines) were considered common (Table 1). 14…”

Section: Ascertainment Of Adverse Eventsmentioning

confidence: 99%

Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine

et al. 2019

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: Human papillomavirus is the most common sexually transmitted infection in the United States and causes certain anogenital and oropharyngeal cancers. The 9valent human papillomavirus vaccine (9vHPV) provides protection against additional types not included in the quadrivalent vaccine. We conducted near real-time vaccine safety surveillance for 24 months after the vaccine became available in the Vaccine Safety Datalink. METHODS: Immunizations and adverse events were extracted weekly from October 2015 to October 2017 from standardized data files for persons 9 to 26 years old at 6 Vaccine Safety Datalink sites. Prespecified adverse events included anaphylaxis, allergic reaction, appendicitis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, injection site reaction, pancreatitis, seizure, stroke, syncope, and venous thromboembolism. The observed and expected numbers of events after 9vHPV were compared weekly by using sequential methods. Both historical and concurrent comparison groups were used to identify statistical signals for adverse events. Unexpected signals were investigated by medical record review and/or additional analyses. RESULTS: During 105 weeks of surveillance, 838 991 doses of 9vHPV were administered. We identified unexpected statistical signals for 4 adverse events: appendicitis among boys 9 to 17 years old after dose 3; pancreatitis among men 18 to 26 years old; and allergic reactions among girls 9 to 17 years old and women 18 to 26 years old after dose 2. On further evaluation, which included medical record review, temporal scan analysis, and additional epidemiological analyses, we did not confirm signals for any adverse events. CONCLUSIONS: After 2 years of near real-time surveillance of 9vHPV and several prespecified adverse events, no new safety concerns were identified. WHAT'S KNOWN ON THIS SUBJECT: Human papillomavirus (HPV) is a common sexually transmitted infection that can cause cancer and other illnesses. Clinical trials of the 9-valent HPV vaccine have demonstrated efficacy and safety, but population-based studies are needed to evaluate its safety profile. WHAT THIS STUDY ADDS: In this postlicensure study, we documented ∼839 000 9-valent HPV doses administered from 2015 to 2017 among persons 9 to 26 years old in the Vaccine Safety Datalink; no new safety concerns were identified. With these findings, we add to the safety profile established in prelicensure clinical trials.

show abstract

Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study

Cited by 23 publications

References 16 publications

Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations

Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine

Contact Info

Product

Resources

About